ES2723437T3 - Procesos y productos intermedios para la preparación de un inhibidor de PDE10 - Google Patents

Procesos y productos intermedios para la preparación de un inhibidor de PDE10 Download PDF

Info

Publication number
ES2723437T3
ES2723437T3 ES15785376T ES15785376T ES2723437T3 ES 2723437 T3 ES2723437 T3 ES 2723437T3 ES 15785376 T ES15785376 T ES 15785376T ES 15785376 T ES15785376 T ES 15785376T ES 2723437 T3 ES2723437 T3 ES 2723437T3
Authority
ES
Spain
Prior art keywords
converting
formula
acid
compound
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15785376T
Other languages
English (en)
Spanish (es)
Inventor
Neil S Cutshall
Jennifer Lynn Gage
Thomas L Little
Wayne Douglas Luke
Elisabeth C A Brot
Marco Jonas
Michael James Mcdermott
Karl E Reineke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Application granted granted Critical
Publication of ES2723437T3 publication Critical patent/ES2723437T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/02Lithium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02Magnesium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ES15785376T 2014-04-28 2015-04-24 Procesos y productos intermedios para la preparación de un inhibidor de PDE10 Active ES2723437T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461985400P 2014-04-28 2014-04-28
PCT/US2015/027647 WO2015167969A1 (en) 2014-04-28 2015-04-24 Processes and intermediates for the preparation of a pde10 inhibitor

Publications (1)

Publication Number Publication Date
ES2723437T3 true ES2723437T3 (es) 2019-08-27

Family

ID=54359190

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15785376T Active ES2723437T3 (es) 2014-04-28 2015-04-24 Procesos y productos intermedios para la preparación de un inhibidor de PDE10

Country Status (13)

Country Link
US (2) US9650368B2 (enExample)
EP (1) EP3137462B1 (enExample)
JP (1) JP6474430B2 (enExample)
KR (1) KR102496552B1 (enExample)
CN (1) CN106459026B (enExample)
AU (1) AU2015253464B2 (enExample)
BR (1) BR112016025287B1 (enExample)
CA (1) CA2946756C (enExample)
ES (1) ES2723437T3 (enExample)
IL (1) IL248585B (enExample)
NZ (2) NZ716494A (enExample)
RU (1) RU2718863C2 (enExample)
WO (1) WO2015167969A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742195T3 (es) * 2010-03-12 2020-02-13 Omeros Corp Inhibidores de PDE10 y composiciones y métodos relacionados
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK178590D0 (da) 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
CZ141795A3 (en) 1992-12-02 1995-11-15 Pfizer 4-substituted catechol diethers as such and for treating diseases and pharmaceutical preparations based thereon
DE4323192A1 (de) 1993-07-10 1995-01-12 Basf Ag Verfahren zur Herstellung von Homo- und Copolymerisaten von Alk-1-enen
DE4325846C1 (de) 1993-07-31 1995-01-19 Herberts Gmbh Verwendung von Furan-modifizierten aromatischen Pinakolderivaten als Initiatoren und Furan-modifizierte aromatische Pinakolderivate als solche
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE4409501A1 (de) 1994-03-19 1995-09-21 Didier Werke Ag Verschleißfutter eines Schachtofens und Stein hierfür
MX9700068A (es) 1994-06-24 1997-12-31 Euro Celtique Sa Compuestos y metodo para inhibir a la fosfodiesterasa iv.
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW424087B (en) 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
DE69728581D1 (de) 1996-01-22 2004-05-13 Fujisawa Pharmaceutical Co Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten
AU4015497A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
JPH1087543A (ja) 1996-09-17 1998-04-07 Chisso Corp アルコキシベンゼン誘導体、液晶組成物および液晶表示素子
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999045914A1 (en) 1998-03-13 1999-09-16 Maruho Kabushikikaisha Alkyl amine derivative and local anesthetic agent using the same
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
CZ20013289A3 (cs) 1999-03-12 2002-01-16 Boehringer Ingelheim Pharmaceuticals, Inc. Sloučeniny výhodné jako protizánětové prostředky
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
BR0209918A (pt) 2001-05-22 2004-03-30 Pfizer Prod Inc Formas cristalinas da azitromicina
EP1499662A1 (en) * 2002-04-18 2005-01-26 Avecia Limited Prepation of a conjugated molecule and materials for use therein
US6821502B2 (en) 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
WO2004011410A1 (en) 2002-07-27 2004-02-05 Astrazeneca Ab Chemical compounds
AU2003275493A1 (en) 2002-10-08 2004-05-04 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
DE60324449D1 (de) 2002-10-30 2008-12-11 Via Pharmaceuticals Inc Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
TW200410921A (en) 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
AU2003289200A1 (en) 2002-12-06 2004-06-30 Kowa Co., Ltd. Erythropoietin production accelerator
JP2006518333A (ja) 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
WO2004094411A1 (en) 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
JP4879165B2 (ja) 2004-04-20 2012-02-22 トランス テック ファーマ,インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
CA2566158A1 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
CN102491969B (zh) 2005-01-07 2015-08-19 辉瑞产品公司 杂芳族喹啉化合物及其作为pde10抑制剂的用途
SG159528A1 (en) 2005-02-04 2010-03-30 Senomyx Inc Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1871770A1 (en) 2005-04-22 2008-01-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CA2617788A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
EA014164B1 (ru) 2005-08-29 2010-10-29 САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи Новая кристаллическая форма производного пиридазино[4,5-в]индола
DE602006019822D1 (de) 2005-09-13 2011-03-10 Sicor Inc Reines rocuroniumbromid
ZA200803758B (en) 2005-11-15 2009-08-26 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
CN101341131A (zh) 2005-12-23 2009-01-07 阿斯利康(瑞典)有限公司 作为gaba-b受体调节剂的咪唑
WO2007129183A2 (en) 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
ES2376493T3 (es) 2006-09-08 2012-03-14 Ore Pharmaceuticals Inc. Procedimiento para reducir o aliviar la inflamación en el tubo digestivo.
SG185979A1 (en) 2006-09-25 2012-12-28 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
AU2007300532A1 (en) 2006-09-28 2008-04-03 Merck Sharp & Dohme Corp. Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes
US20090253918A1 (en) 2006-10-02 2009-10-08 Janssen Pharmaceuticals, N.V. Novel intermediate for glyt1 inhibitor
US7837978B2 (en) 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2008064342A2 (en) * 2006-11-21 2008-05-29 Omeros Corporation Pde10 inhibitors and related compositions and methods
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
CA2687647A1 (en) 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal
EP2017264A1 (de) 2007-07-16 2009-01-21 Bayer Cropscience Ag Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2009049022A1 (en) 2007-10-10 2009-04-16 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
TW200944520A (en) 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2009143178A2 (en) 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物
ES2654617T3 (es) 2008-08-05 2018-02-14 Omeros Corporation Inhibidores de PDE10 y composiciones y procedimientos relacionados
ES2742195T3 (es) 2010-03-12 2020-02-13 Omeros Corp Inhibidores de PDE10 y composiciones y métodos relacionados
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor

Also Published As

Publication number Publication date
AU2015253464B2 (en) 2018-11-22
CN106459026B (zh) 2019-07-05
NZ716494A (en) 2017-07-28
JP2017513885A (ja) 2017-06-01
AU2015253464A1 (en) 2016-10-27
CA2946756C (en) 2022-03-29
BR112016025287A2 (pt) 2017-08-15
US20160024069A1 (en) 2016-01-28
KR20160147275A (ko) 2016-12-22
WO2015167969A1 (en) 2015-11-05
BR112016025287B1 (pt) 2022-10-11
KR102496552B1 (ko) 2023-02-06
RU2016146118A (ru) 2018-05-30
IL248585B (en) 2020-03-31
EP3137462A1 (en) 2017-03-08
RU2718863C2 (ru) 2020-04-15
RU2016146118A3 (enExample) 2018-12-24
CN106459026A (zh) 2017-02-22
JP6474430B2 (ja) 2019-02-27
EP3137462A4 (en) 2017-12-27
US20180057484A1 (en) 2018-03-01
IL248585A0 (en) 2016-12-29
EP3137462B1 (en) 2019-01-30
CA2946756A1 (en) 2015-11-05
US9650368B2 (en) 2017-05-16
NZ630810A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
MX2015013105A (es) Catalizador de etinilación novedoso y método para prepararlo.
MX346922B (es) Moderación de suciedad en procesos de hidroformilación mediante adición de agua.
SA515370018B1 (ar) مركب سائل أيوني
MY172419A (en) Hydroformylation process
AR105494A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
BR112016008895A8 (pt) métodos para formação de compostos homoalílicos pela reação de precursores de ciclopropilvinila com ácido de bronsted, e para formação de ambrox
ES2723437T3 (es) Procesos y productos intermedios para la preparación de un inhibidor de PDE10
AR084864A1 (es) Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso
MX2022014035A (es) Proceso para la ciclopropanacion de olefinas utilizando compuestos de n-metil-n-nitroso.
MX2015013589A (es) Proceso e intermediario para la preparacion de pregabalina.
BR112015018018A2 (pt) Processo para a preparação de hidróxi aldeído
NZ716462A (en) Optically active pde10 inhibitor
IN2015DN00665A (enExample)
PH12018500677A1 (en) Method for producing optically active 2- (2-fluorobiphenyl-4-yl) propanoic acid
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
EA028190B9 (ru) Монооксид азота в качестве катализатора цис/транс-изомеризации ненасыщенных соединений
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
AR106195A1 (es) Proceso para la preparación de ácido 1-(4-metanosulfonil-2-trifluorometil-bencil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético e intermediarios de dicha síntesis
ES2721446T3 (es) Método para producir un compuesto de éster del ácido ciclopropano carboxílico ópticamente activo, un complejo de cobre asimétrico y un compuesto de salicilidenoaminoalcohol ópticamente activo
MD20140048A2 (ru) Способ синтеза 3,4-диметоксибицикло¢4.2.0]окта-1,3,5-триен-7-карбонитрила и его применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MX2017003290A (es) Proceso para la preparacion de derivados de trifenilbuteno.
MY156194A (en) Method for producing or method for storing liquid composition containing tetrahydro-4h-1,3,5-oxadiazin-4-one
MX2013011604A (es) Metodo para la remocion del diester ciclico de un acido 2-hidroxialcanoico de un vapor.
AR107875A1 (es) Método para acoplar un primer compuesto a un segundo compuesto
RU2013117246A (ru) Способ получения этиламин(n→b)-бората